Nefrologia最新文献

{"title":"Tixagevimab-cilgavimab como tratamiento profiláctico preexposición frente a SARS-CoV-2 en pacientes trasplantados renales","authors":"Luis Bravo González-Blas ,&nbsp;Natalia Menéndez García ,&nbsp;María Fernández Prada ,&nbsp;María Gago Fraile ,&nbsp;María Luisa Suárez Fernández ,&nbsp;Natalia Ridao Cano","doi":"10.1016/j.nefro.2023.03.005","DOIUrl":"10.1016/j.nefro.2023.03.005","url":null,"abstract":"<div><h3>Introduction</h3><p>It has been reported that after vaccination with RNAm or viral vectors from SARS-CoV-2 a significant number of solid organ transplant recipients do not develop an effective immune response. In this scenario, the use of tixagevimab-cilgavimab was approved by the European Medicines Agency for COVID-19 prophylaxis in immunocompromised patients in March 2022. We present our experience with a group of kidney transplant recipients who received prophylactic treatment with tixagevimab-cilgavimab.</p></div><div><h3>Material and methods</h3><p>Prospective study from a cohort of kidney transplant recipients who had been previously vaccinated with 4 doses and did not achieve a satisfactory immune response to vaccination, presenting antibody titers lower than 260 BAU/mL when measured by ELISA. A total of 55 patients who received a single dose of 150<!--> <!-->mg of tixagevimab and 150<!--> <!-->mg of cilgavimab between May and September of 2022 were included in this study.</p></div><div><h3>Results</h3><p>No immediate or severe adverse reactions, including worsening of kidney function, were observed after administering the drug or during follow up. All patients who had received the drug 3 months prior presented positive antibody titers (&gt;<!--> <!-->260 BAU/mL). Seven patients were diagnosed with COVID, and one of those patients had to be admitted to the hospital and died 5 days later from infectious complications and a suspected diagnosis of bacterial coinfection.</p></div><div><h3>Conclusions</h3><p>In our experience, all kidney transplant recipients reached antibody titers higher than 260 BAU/mL 3 months after receiving prophylactic treatment with tixagevimab-cilgavimab with no severe or irreversible adverse reactions.</p></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9712478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between CYP4A11 and EPHX2 genetic polymorphisms and chronic kidney disease progression in hypertensive patients","authors":"Miguel A. Suárez-Santisteban ,&nbsp;Gracia Santos-Díaz ,&nbsp;Vanesa García-Bernalt ,&nbsp;Ana M. Pérez-Pico ,&nbsp;Esther Mingorance ,&nbsp;Raquel Mayordomo ,&nbsp;Pedro Dorado","doi":"10.1016/j.nefro.2023.08.002","DOIUrl":"10.1016/j.nefro.2023.08.002","url":null,"abstract":"<div><h3>Background</h3><p>There is evidence indicating that some metabolites of arachidonic acid produced by cytochromes P450 (CYP) and epoxide hydroxylase (<em>EPHX2</em>), such as hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids (EETs) or dihydroxyeicosatrienoic acids (DHETEs), play an important role in blood pressure regulation and they could contribute to the development of hypertension (HT) and kidney damage. Therefore, the main aim of the study was to evaluate whether the genetic polymorphisms of <em>CYP2C8</em>, <em>CYP2C9</em>, <em>CYP2J2</em>, <em>CYP4F2</em>, <em>CYP4F11</em> and <em>EPHX2</em>, responsible for the formation of HETEs, EETs and DHETEs, are related to the progression of impaired renal function in a group of patients with hypertension.</p></div><div><h3>Methods</h3><p>151 HT patients from a hospital nephrology service were included in the study. Additionally, a group of 87 normotensive subjects were involved in the study as control group. For HT patients, a general biochemistry analysis, estimated glomerular filtration rate and genotyping for different <em>CYPs</em> and <em>EPHX2</em> variant alleles were performed.</p></div><div><h3>Results</h3><p><em>CYP4A11</em> rs3890011, rs9332982 and <em>EPHX2</em> rs41507953 polymorphisms, according to the dominant model, presented a high risk of impaired kidney function, with odds ratios (OR) of 2.07 (1.00–4.32; <em>P</em> <!-->=<!--> <!-->0.049), 3.02 (1.11–8.23; <em>P</em> <!-->=<!--> <!-->0.030) and 3.59 (1.37–9.41; <em>P</em> <!-->=<!--> <!-->0.009), respectively, and the <em>EPHX2</em> rs1042032 polymorphism a greater risk according to the recessive model (OR<!--> <!-->=<!--> <!-->6.23; 95% CI<!--> <!-->=<!--> <!-->1.50–25.95; <em>P</em> <!-->=<!--> <!-->0.007). However, no significant differences in allele frequencies between HT patients and in normotensive subjects for any of the SNP analyzed. In addition, the patients with diagnosis of dyslipidemia (<em>n</em> <!-->=<!--> <!-->90) presented higher frequencies of <em>EPHX2 K55R</em> (rs41507953) and <em>*35A</em>&gt;<em>G</em> (rs1042032) variants than patients without dyslipidemia, 4% <em>vs.</em> 14% (<em>P</em> <!-->=<!--> <!-->0.005) and 16 <em>vs</em>. 27% (<em>P</em> <!-->=<!--> <!-->0.02), respectively.</p></div><div><h3>Conclusions</h3><p>In this study has been found higher odds of impaired renal function progression associated with rs3890011 and rs9332982 (<em>CYP4A11</em>) and rs41507953 and rs1042032 (<em>EPHX2</em>) polymorphisms, which may serve as biomarkers for improve clinical interventions aimed at avoiding or delaying, in chronic kidney disease patients, progress to end-stage kidney disease needing dialysis or kidney transplant.</p></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523001273/pdfft?md5=80c20c1fdc4df59f7be44d5285595070&pid=1-s2.0-S0211699523001273-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45238530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glomerulonefritis proliferativa mesangial y endocapilar e infección por escabiosis. ¿Una relación causal o circunstancial?","authors":"Miguel Ángel González Martínez,&nbsp;María Ramírez Gómez,&nbsp;Vanesa García Chumillas","doi":"10.1016/j.nefro.2023.09.005","DOIUrl":"10.1016/j.nefro.2023.09.005","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523001467/pdfft?md5=fe60fd3464f6b477e040b180c836ea28&pid=1-s2.0-S0211699523001467-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135347016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlación entre el sodio plasmático determinado por el laboratorio y el determinado por el monitor de hemodiálisis","authors":"Joaquim Casals ,&nbsp;José Jesús Broseta ,&nbsp;Rosa María Fernández ,&nbsp;Diana Rodriguez-Espinosa ,&nbsp;Jimena del Risco ,&nbsp;Miquel Gómez ,&nbsp;Lida M. Rodas ,&nbsp;Marta Arias-Guillén ,&nbsp;Manel Vera ,&nbsp;Néstor Fontseré ,&nbsp;Naira Rico ,&nbsp;Francisco Maduell","doi":"10.1016/j.nefro.2023.09.004","DOIUrl":"10.1016/j.nefro.2023.09.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Changes in plasma sodium concentration (_pNa, expressed in mEq/l) are common in hemodialysis (HD) patients. Hemodialysis monitors can estimate _pNa by using an internal algorithm based on ionic dialysance measurements. The present study studies the accuracy of the correlation between the _pNa estimated by the dialysis monitor and that measured by the biochemistry laboratory at our center.</p></div><div><h3>Material and methods</h3><p>A single-centre prospective observational study in patients on a chronic HD program with the 6008 CAREsystem monitor and standard sodium (138<!--> <!-->mEq/l) and bicarbonate (32<!--> <!-->mmol/l) prescriptions. Venous blood samples were drawn from each patient before and after each HD session to ensure inter- and intra-individual validity. The _pNa was measured in the biochemistry laboratory using indirect potentiometry and simultaneously the estimated _pNa by the HD monitor was recorded at the beginning and at the end of the HD session. For statistical analysis, a scatter plot was made, and Spearman's correlation quotient was calculated. In addition, the differences between both methods were represented as Bland-Altman diagrams.</p></div><div><h3>Results</h3><p>The pre-dialysis _pNa measured in the laboratory was 137.49<!--> <!-->±<!--> <!-->3.3, and that of the monitor, 137.96<!--> <!-->±<!--> <!-->2.91, with a correlation with <em>R</em>² value of 0.683 (<em>P</em>&lt;.001). The post-dialysis _pNa measured in the laboratory was 137.08<!--> <!-->±<!--> <!-->2.23, and that of the monitor was 138.87<!--> <!-->±<!--> <!-->1.88, with an <em>R</em>² of 0.442 (<em>P</em>&lt;.001). On the Bland-Altman plots, the pre-dialysis _pNa has a systematic error of 0.49, in favor of the monitor-estimated _pNa, with a 95% confidence interval (CI) of (−3.24 to a 4.22). In the post-dialysis _pNa, a systematic error of 1.79 with a 95% CI of (−1.64 to 5.22) was obtained.</p></div><div><h3>Conclusion</h3><p>The correlation between the _pNa estimated by Fresnius 6008 CAREsystem HD monitor and that measured by the laboratory is good, especially pre-dialysis measurements. Further studies should verify the external validity of these results.</p></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523001455/pdfft?md5=674d1cc66e024ca904a886eb140428a9&pid=1-s2.0-S0211699523001455-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135389896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guía clínica de adecuación y prescripción de la diálisis peritoneal","authors":"Mercè Borràs Sans ,&nbsp;Esther Ponz Clemente ,&nbsp;Ana Rodríguez Carmona ,&nbsp;Manel Vera Rivera ,&nbsp;Miguel Pérez Fontán ,&nbsp;Carlos Quereda Rodríguez-Navarro ,&nbsp;M. Auxiliadora Bajo Rubio ,&nbsp;Verónica de la Espada Piña ,&nbsp;Mercedes Moreiras Plaza ,&nbsp;Javier Pérez Contreras ,&nbsp;Gloria del Peso Gilsanz ,&nbsp;Mario Prieto Velasco ,&nbsp;Pedro Quirós Ganga ,&nbsp;César Remón Rodríguez ,&nbsp;Emilio Sánchez Álvarez ,&nbsp;Nicanor Vega Rodríguez ,&nbsp;Nuria Aresté Fosalba ,&nbsp;Yolanda Benito ,&nbsp;M. José Fernández Reyes ,&nbsp;Isabel García Martínez ,&nbsp;Ana Usón Nuño","doi":"10.1016/j.nefro.2024.03.001","DOIUrl":"10.1016/j.nefro.2024.03.001","url":null,"abstract":"<div><p>In recent years, the meaning of adequacy in peritoneal dialysis has changed. We have witnessed a transition from an exclusive achievement of specific objectives —namely solute clearances and ultrafiltration— to a more holistic approach more focused to on the quality of life of these patients. The purpose of this document is to provide recommendations, updated and oriented to social and health environment, for the adequacy and prescription of peritoneal dialysis. The document has been divided into three main sections: adequacy, residual kidney function and prescription of continuous ambulatory peritoneal dialysis and automated peritoneal dialysis. Recently, a guide on the same topic has been published by a Committee of Experts of the International Society of Peritoneal Dialysis (ISPD 2020). In consideration of the contributions of the group of experts and the quasi-simultaneity of the two projects, references are made to this guide in the relevant sections. We have used a systematic methodology (GRADE), which specifies the level of evidence and the strength of the proposed suggestions and recommendations, facilitating future updates of the document.</p></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699524000225/pdfft?md5=2b759665e67196fe53a8f3cc90f3e523&pid=1-s2.0-S0211699524000225-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140273380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uso compasivo de tolvaptán en megacolon adquirido secundario a poliquistosis renal autosómica dominante (PQRAD)","authors":"Iris Viejo Boyano ,&nbsp;Paul José Hernández Velasco ,&nbsp;Eduardo Gutiérrez Martínez","doi":"10.1016/j.nefro.2023.01.007","DOIUrl":"10.1016/j.nefro.2023.01.007","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523000085/pdfft?md5=02c769a76c3a0b0772fbe4eaed6a6946&pid=1-s2.0-S0211699523000085-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48418111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vasculitis crioglobulinémica y glomerulonefritis membranoproliferativa en paciente con infección por virus C curada","authors":"Ester Casillas Sagrado ,&nbsp;Candela Moliz Cordón ,&nbsp;Ana Sainz González ,&nbsp;Vanessa Lopes Martín ,&nbsp;Milagros Fernández Lucas ,&nbsp;Javier Villacorta Pérez","doi":"10.1016/j.nefro.2022.02.004","DOIUrl":"10.1016/j.nefro.2022.02.004","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699522000340/pdfft?md5=b7e3c939d7469bfd9d9f6a9cd1c1fe39&pid=1-s2.0-S0211699522000340-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43216743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulation of ferroptosis may participate in the mitigating effect of CoCl2 on contrast-induced nephropathy","authors":"Huilin Li ,&nbsp;Shuang Liu ,&nbsp;Dan Zhang ,&nbsp;Xue Zong ,&nbsp;Gengru Jiang ,&nbsp;Chun Zhu","doi":"10.1016/j.nefro.2023.08.007","DOIUrl":"10.1016/j.nefro.2023.08.007","url":null,"abstract":"<div><h3>Background</h3><p>Contrast agents can directly or indirectly induce renal tubular ischemia and hypoxic damage. Given that cobalt chloride (CoCl₂) can protect renal tubules, the protective effect and potential mechanism of action of CoCl₂ on contrast-induced nephropathy (CIN) warrant investigation.</p></div><div><h3>Methods</h3><p>A CIN mouse model was established to determine the protective effect of CoCl₂ on renal injury <em>in vivo</em>. Then, TMT-based proteomics was performed to determine the differentially expressed proteins (DEPs), following which, enrichment analyses of gene ontology and the KEGG pathway were performed. <em>In vitro</em>, a CIN model was constructed with renal tubular epithelial cells (HK-2) to determine the effect of CoCl₂ on potential targets and the role of the key protein identified from the <em>in vivo</em> experiments.</p></div><div><h3>Results</h3><p>CoCl₂ treatment decreased the levels of BUN and serum creatinine (sCr), while increasing the levels of urea and creatinine (Cr) in the urine of mice after CIN injury. Damage to the renal tubules in the CoCl₂ treatment group was significantly less than in the CIN model group. We identified 79 DEPs after treating the <em>in vivo</em> model with CoCl₂, and frequently observed ferroptosis-related GO and KEGG pathway terms. Of these, Hp (haptoglobin) was selected and found to have a strong renoprotective effect, even though its expression level in kidney tissue decreased after CoCl₂ treatment. In HK-2 cells, overexpression of Hp reduced the ferroptosis caused by erastin, while knocking down Hp negated the attenuation effect of CoCl₂ on HK-2 cell ferroptosis.</p></div><div><h3>Conclusion</h3><p>CoCl₂ attenuated kidney damage in the CIN model, and this effect was associated with the decrease in ferroptosis mediated by Hp.</p></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523001388/pdfft?md5=a82cd559a6c97c086aaa5885221a2789&pid=1-s2.0-S0211699523001388-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45706696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estrategias de prevención y tratamiento de la infección por SARS-CoV-2 (Severe Acute Respiratory Coronavirus 2) en pacientes con enfermedad renal crónica: revisión de la literatura","authors":"María Marques Vida ,&nbsp;Elena Muñez Rubio ,&nbsp;Borja Quiroga ,&nbsp;Rocío Montejano ,&nbsp;Enrique Morales ,&nbsp;Francisco Javier Candel","doi":"10.1016/j.nefro.2023.10.002","DOIUrl":"10.1016/j.nefro.2023.10.002","url":null,"abstract":"<div><p>COVID-19 has proven to be particularly aggressive in patients with chronic kidney disease (CKD). The lower immune response rate and the greater susceptibility to progress to severe forms of the disease have contributed to this phenomenon, which has persisted in the post-vaccination era of the pandemic. Paradoxically, CKD has been excluded from most clinical trials of the main therapeutic tools developed against SARS-CoV-2. However, experience in the use of these drugs has been accumulating in different stages of CKD, supporting their use with guarantees of efficacy and safety.</p><p>The objective of this review is to gather all treatment indications for COVID-19 in the different phases of the disease, tailored to CKD in its various stages, including renal replacement therapy.</p></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523001534/pdfft?md5=2769d35d6100ca4d6ccc6b7b51093af5&pid=1-s2.0-S0211699523001534-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135660752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nefropatía por poliomavirus JC en paciente trasplantado renal, un invitado infrecuente","authors":"Cristo Adonay Santana Quintana ,&nbsp;Roberto Gallego Samper ,&nbsp;María José Pena López ,&nbsp;Rafael Camacho Galán ,&nbsp;Raquel Santana Estupiñán ,&nbsp;Sara Aladro Escribano ,&nbsp;Juan Carlos Quevedo Reina ,&nbsp;Daniel Medina García ,&nbsp;Yuliana Stefanía Daruiz D‘Orazio ,&nbsp;Patricia Pérez Borges","doi":"10.1016/j.nefro.2023.02.001","DOIUrl":"10.1016/j.nefro.2023.02.001","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523000279/pdfft?md5=6727609240003db0f1eae96852c38a18&pid=1-s2.0-S0211699523000279-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45748710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}